Quality Assurance Associate
Krystal Biotech
Quality Assurance Associate
Krystal Biotech
Dermatology-focused topical gene therapies
Dermatology-focused topical gene therapies
Krystal Biotech develops and sells gene therapies for rare dermatological diseases. Its lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy designed to treat dystrophic epidermolysis bullosa (DEB) by delivering a corrected gene directly to the skin so that damaged skin can heal. The company’s STAR-D platform enables off-the-shelf gene therapies that can be used across a range of skin conditions and the VYJUVEK therapy is designed to be redoable, meaning its treatment can be repeated if needed. Krystal Biotech stands out by owning exclusive worldwide rights to its therapies and by being the first FDA-approved medicine for DEB, a rare condition. The company’s goal is to grow its portfolio of dermatology gene therapies using the STAR-D platform to provide accessible, repeatable treatments for patients with rare skin diseases.
Explore more opportunities at Krystal Biotech